United Therapeutics Corporation (UTHR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
UTHR Revenue Growth
Revenue Breakdown (FY 2025)
UTHR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
UTHR Revenue Analysis (2014–2025)
As of May 7, 2026, United Therapeutics Corporation (UTHR) generated trailing twelve-month (TTM) revenue of $3.17 billion, reflecting slight decline in growth of -1.6% year-over-year. The most recent quarter (Q1 2026) recorded $781.5 million in revenue, down 1.1% sequentially.
Looking at the longer-term picture, UTHR's 5-year compound annual growth rate (CAGR) stands at +16.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $3.18 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows UTHR's business is primarily driven by Tyvaso (59%), Remodulin (17%), and Orenitram (16%). With over half of revenue concentrated in Tyvaso, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IDYA (+3118.1% YoY), RARE (+13.3% YoY), and ACAD (+11.9% YoY), UTHR has underperformed the peer group in terms of revenue growth. Compare UTHR vs IDYA →
UTHR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UTHRCurrent | $3.2B | -1.6% | +16.5% | 46.9% | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +11.9% | +19.4% | 9.8% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
UTHR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.18B | +10.6% | $2.80B | 87.9% | $1.49B | 46.9% |
| 2024 | $2.88B | +23.6% | $2.57B | 89.2% | $1.38B | 47.9% |
| 2023 | $2.33B | +20.2% | $2.07B | 88.9% | $1.18B | 50.9% |
| 2022 | $1.94B | +14.9% | $1.79B | 92.4% | $979.7M | 50.6% |
| 2021 | $1.69B | +13.6% | $1.56B | 92.7% | $555.9M | 33.0% |
| 2020 | $1.48B | +2.4% | $1.38B | 92.7% | $593.6M | 40.0% |
| 2019 | $1.45B | -11.0% | $1.33B | 91.9% | $-187,600,000 | -12.9% |
| 2018 | $1.63B | -5.7% | $1.43B | 87.8% | $805.4M | 49.5% |
| 2017 | $1.73B | +7.9% | $1.62B | 93.9% | $814.9M | 47.2% |
| 2016 | $1.60B | +9.1% | $1.53B | 95.5% | $1.06B | 66.4% |
Full UTHR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See UTHR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UTHR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UTHR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUTHR — Frequently Asked Questions
Quick answers to the most common questions about buying UTHR stock.
Is UTHR's revenue growth accelerating or slowing?
UTHR revenue growth slowed to -1.6%, below the 5-year CAGR of +16.5%. TTM revenue is $3.2B. The deceleration marks a shift from historical growth rates.
What is UTHR's long-term revenue growth rate?
United Therapeutics Corporation's 5-year revenue CAGR of +16.5% reflects the variable expansion pattern. Current YoY growth of -1.6% is near this long-term average.
How is UTHR's revenue distributed by segment?
UTHR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.